This benefit should be taken into consideration when prescribing P2Y12 inhibitor to patients with high risk of pneumonia, such as the elderly, smokers, COPD patients, and the immunosuppressed. This evidence concerns the gene P2RY12 and susceptibility to pneumonia measurement.